These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 18822884)

  • 1. [Investigation of anti-R7V antibodies in HIV-infected patients under highly active antiretroviral therapy].
    Ergünay K; Altinbaş A; Calik Başaran N; Unal S; Us D; Karabulut E; Ustaçelebi S
    Mikrobiyol Bul; 2008 Jul; 42(3):413-9. PubMed ID: 18822884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and studies of the anti-R7V neutralizing antibody ELISA test: a new serological test for HIV seropositive patients.
    Sanchez A; Gemrot F; Da Costa Castro JM
    J Immunol Methods; 2008 Mar; 332(1-2):53-60. PubMed ID: 18234206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
    J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant human monoclonal anti-R7V antibody as a potential therapy for HIV infected patients in failure of HAART.
    Haslin C; Lévêque M; Ozil A; Cérutti P; Chardès T; Chermann JC; Duonor-Cérutti M
    Hum Antibodies; 2007; 16(3-4):73-85. PubMed ID: 18334743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome.
    Murdaca G; Contini P; Setti M; Cagnati P; Villa R; Lantieri F; Indiveri F; Puppo F
    Hum Immunol; 2007 Nov; 68(11):894-900. PubMed ID: 18082568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preliminary investigation on the relation between clinical progress and anti-small monomolecular peptides antibody in individual infected with HIV].
    Xu X; Xing H; Gong W; Chen H; Si C; Wang Y; Chermann JC
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):286-7. PubMed ID: 12665943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated levels of antibodies against 70 kDa heat shock proteins in the sera of patients with HIV infection.
    Kocsis J; Prohászka Z; Bíró A; Füst G; Bánhegyi D
    J Med Virol; 2003 Dec; 71(4):480-2. PubMed ID: 14556258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy.
    Gaardbo JC; Nielsen SD; Vedel SJ; Ersbøll AK; Harritshøj L; Ryder LP; Nielsen JO; Kolte L
    Clin Exp Immunol; 2008 Oct; 154(1):80-6. PubMed ID: 18821942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy.
    Simonelli C; Tedeschi R; Gloghini A; Bortolin MT; Spina M; Bidoli E; Cinelli R; De Paoli P; Carbone A; Tirelli U
    Clin Infect Dis; 2005 Apr; 40(7):1022-7. PubMed ID: 15824995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
    French M; Keane N; McKinnon E; Phung S; Price P
    HIV Med; 2007 Apr; 8(3):148-55. PubMed ID: 17461858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy.
    Chitra P; Bakthavatsalam B; Palvannan T
    Clin Chim Acta; 2011 May; 412(11-12):1151-4. PubMed ID: 21300045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection.
    Carter LM; Peters BS; Ellis BA; Wolstencroft RA
    J Infect; 2000 Nov; 41(3):252-5. PubMed ID: 11120614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
    López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
    Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2 and IL-10 serum levels in HIV-1-infected patients with or without active antiretroviral therapy.
    Orsilles MA; Pieri E; Cooke P; Caula C
    APMIS; 2006 Jan; 114(1):55-60. PubMed ID: 16499662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.